This disclosure provides a novel strategy to cope with chronic virus infection by introducing a dominant negative viral structural protein to disturb effective virion production. The dominant negative structural protein mimics antiviral drugs through structural and biochemical interactions during virus assembly. An effective gene therapy model for chronic viral infected diseases is proposed in this disclosure, as represented by HBV Cpdominant 1 to clear viral infection.
